<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134301</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-ORI-11-01</org_study_id>
    <nct_id>NCT02134301</nct_id>
  </id_info>
  <brief_title>Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections</brief_title>
  <official_title>An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melinta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melinta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Phase 1 trial is to evaluate the pharmacokinetics, safety and&#xD;
      tolerability of oritavancin in patients &lt;18 years old with a confirmed or suspected bacterial&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multicenter, open-label, PK, safety and tolerability study of oritavancin&#xD;
      in pediatric patients (&lt;18 years of age) with suspected or diagnosed Gram-positive bacterial&#xD;
      infections or pediatric patients requiring peri-operative prophylactic antibiotics.&#xD;
      Approximately 52 patients will be enrolled at 5-10 US centers. This study will include 5 age&#xD;
      cohorts and patients will be entered in a stepwise approach starting with the older age&#xD;
      cohort (12-&lt;18 years). The starting dose will be IV oritavancin 15 mg/kg. The safety,&#xD;
      tolerability and PK data will be reviewed at the completion of each cohort to ensure safety&#xD;
      and determine the appropriate dose for the next age cohort. At least 8 patients will be&#xD;
      enrolled in each cohort except for the birth to &lt;3 month age cohort which will have at least&#xD;
      16 patients enrolled. Three PK samples will be collected over 14 days. The safety follow-up&#xD;
      will complete with a 60-day phone call to the caregiver.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter (Area under the plasma concentration time-curve [AUC])</measure>
    <time_frame>336 hours post infusion start time</time_frame>
    <description>PK parameters (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters</measure>
    <time_frame>336 hours post infusion start time</time_frame>
    <description>PK parameters (Cmax, half-life, tmax, volume of distribution and clearance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>Up to Day 60 post-dose</time_frame>
    <description>Safety of oritavancin assessed according to clinical laboratory parameters, and adverse events (AEs) and serious adverse events (SAEs) up to 60 days following termination of the study drug infusion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Gram Positive Bacterial Infections</condition>
  <arm_group>
    <arm_group_label>Oritavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single-Dose IV Oritavancin Diphosphate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oritavancin</intervention_name>
    <arm_group_label>Oritavancin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females &lt;18 years of age&#xD;
&#xD;
          -  Neonates must be at least 34 weeks post-conception age&#xD;
&#xD;
          -  Parent or legal guardian has given informed consent, as appropriate; and pediatric&#xD;
             patient has given verbal assent where appropriate.&#xD;
&#xD;
          -  Suspected or diagnosed Gram positive bacterial infection for which the subject is&#xD;
             receiving standard antibiotic therapy; or peri-operative prophylactic use of&#xD;
             antibiotics&#xD;
&#xD;
          -  Intravenous access to administer study drug&#xD;
&#xD;
          -  The subject will be observed in the emergency room or hospital for at least 1 hour&#xD;
             after the study drug infusion is completed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Septic shock or acute haemodynamic instability.&#xD;
&#xD;
          -  History of immune-related hypersensitivity reaction to glycopeptides (such as&#xD;
             vancomycin, dalbavancin, televancin, or teicoplanin) or any of their excipients.&#xD;
&#xD;
          -  Subjects who have taken vancomycin, telavancin, teicoplanin or other glycopeptide&#xD;
             within 24 hours of screening or who are anticipated to need these drugs within 48&#xD;
             hours after administration of study drug. Subjects who have taken dalbavancin are&#xD;
             excluded if taken within the previous 2 weeks or who are anticipated to need&#xD;
             dalbavancin within 48 hours after administration of study drug.&#xD;
&#xD;
          -  Females who are of childbearing potential and unwilling to practice abstinence or use&#xD;
             at least two methods of contraception or female patients of childbearing who are&#xD;
             lactating or have a positive pregnancy test result at screening&#xD;
&#xD;
          -  Males who are unwilling to practice abstinence or use an acceptable method of birth&#xD;
             control during the entire study period&#xD;
&#xD;
          -  Any surgical or medical condition which, in the opinion of the investigator, would put&#xD;
             the patient at increased risk or is likely to interfere with study procedures or PK of&#xD;
             the study drug.&#xD;
&#xD;
          -  Patients whom the investigator considers unlikely to adhere to the protocol, comply&#xD;
             with study drug administration, or complete the clinical study&#xD;
&#xD;
          -  Treatment with investigational medicinal product or investigational device within 30&#xD;
             days (or 5 times the half-life of the investigational medicine, whichever is longer)&#xD;
             before enrollment and for the duration of the study.&#xD;
&#xD;
          -  Any clinically significant disease or condition affecting a major organ system,&#xD;
             including but not limited to gastrointestinal, renal, hepatic, endocrinologic,&#xD;
             broncho-pulmonary, neurological, metabolic or cardiovascular disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Fusaro</last_name>
    <role>Study Director</role>
    <affiliation>Melinta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Fusaro</last_name>
    <phone>908-617-1319</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CHOC Children's</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Enriquez</last_name>
      <phone>714-509-4791</phone>
      <email>cenriquez@CHOC.ORG</email>
    </contact>
    <investigator>
      <last_name>Antonio Arrieta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Hingtgen, RN, MSN</last_name>
      <phone>858-966-8450</phone>
      <email>shingtgen@rchsd.org</email>
    </contact>
    <contact_backup>
      <last_name>Mike Farrell, RN, BSN</last_name>
      <phone>858-966-8450</phone>
      <email>mfarrell@rchsd.org</email>
    </contact_backup>
    <investigator>
      <last_name>John Bradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbour-UCLA Medcial Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Kosair Charities Pediatric Clinical Research Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudia Espinosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Goodwin</last_name>
      <phone>402-559-0681</phone>
      <email>jennifer.goodwin@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Kari A Simonsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Toledo Children's Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oritavancin</keyword>
  <keyword>pediatrics</keyword>
  <keyword>gram positive</keyword>
  <keyword>bacterial infection</keyword>
  <keyword>Confirmed</keyword>
  <keyword>Suspected</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Positive Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oritavancin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

